% | $
Quotes you view appear here for quick access.

Peregrine Pharmaceuticals, Inc. Message Board

  • asmarterwookie asmarterwookie Feb 14, 2013 8:11 PM Flag

    Dear Stockholders, (from the2012 Annual Report)

    Dear Stockholders,
    This is a truly transformative time for Peregrine.
    We are transitioning from an early-stage research organization to a late-stage drug development company, thanks
    to an expanding product pipeline that now includes two Phase III-ready programs, exceptional proof-of-concept
    clinical data for our lead product candidate bavituximab and a record-breaking revenue year for our contract
    manufacturing business. Taken together, this has been an exciting year of growth that has set the stage for success
    now and into the future.
    By diligently executing our strategy, today we are positioned with two advanced programs from our oncologyfocused
    pipeline ready for Phase III development. Over the last year, we made great strides in exploring the
    potential of our proprietary phosphatidylserine (PS)-targeting platform including our lead PS-targeting antibody
    bavituximab and in advancing our other business goals. Achievements over the past year included:...

    Best of Better Data and Luck


    Sentiment: Strong Buy

0.427-0.003(-0.70%)11:05 AMEDT